Drug Discovery MedicineMedicine and Medical Science

M.D., Ph.D. Professor Hagiwara, Masatoshi

At the Department of Drug Discovery Medicine, we work closely with supporting pharmaceutical companies and nurture people with talents required for drug discovery and development in a new era. We accept both medical graduates and graduates from other disciplines for our master’s and doctoral program. The goal of our curriculum is to make graduates ready to work in a wide variety of positions in drug discovery and development, including (not limited) researchers both in academia and pharmaceutical companies, entrepreneurs, managers in drug discovery and development, and managers in academia-pharma collaboration.

Lab Website

Research and Education

In Layer 1 of our program, lectures and laboratory courses will be provided for non-MD students to acquire systematic knowledge of core basic science in medicine. In Layer 2, all students further acquire essential knowledge in the current drug discovery and development such as clinical human genetics, bioinformatics, etc. and, in Layer 3, they participate in a series of seminars studying pathophysiology of human diseases and engaging in active discussion on target identification and development of new therapeutic modalities using several diseases as representative examples. Finally, in Layer 4, trainees are exposed to studies in wider areas related to drug discovery and development such as bio-bank, big data science, precision medicine, clinical trials, intellectual properties, regulatory science, and business models, all of which are important in filling gaps among academia, companies and society to facilitate delivery of drugs to the patients. In parallel with such educational course works, students conduct their own research projects by participating in academia-pharma collaborative projects ongoing at the Medical Innovation Center and other departments of Kyoto University.

Recent Publications

  1. Matsushima S, Ajiro M, Iida K, Chamoto K, Honjo T, Hagiwara M. (2022) Chemical induction of splice-neoantigens attenuates tumor growth in a preclinical model of colorectal cancer. Sci Transl Med. 14(673):eabn6056.
  2. Ajiro M, Awaya T, Kim YJ, Iida K, Denawa M, Tanaka N, Kurosawa R, Matsushima S, Shibata S, Sakamoto T, Studer L, Krainer AR, Hagiwara M. (2021) Therapeutic manipulation of IKBKAP mis-splicing with a small molecule to cure familial dysautonomia. Nat Commun. 12(1):4507.
  3. Thumkeo D, Katsura Y, Nishimura Y, Kanchanawong P, Tohyama K, Ishizaki T, Kitajima S, Takahashi C, Hirata T, Watanabe N, Krummel MF, Narumiya S. (2020) mDia1/3-dependent actin polymerization spatiotemporally controls LAT phosphorylation by Zap70 at the immune synapse. Science Advances, 6(1), eaay2432
  4. Thumkeo, D., Punyawatthananukool, S., Prasongtanakij, S., Matsuura, R., Arima, K., Nie, H., Yamamoto, R., Aoyama, N., Hamaguchi, H., Sugahara, S., Takeda, S., Charoensawan, V., Tanaka, A., Sakaguchi, S. and Narumiya S. (2022) PGE2-EP2/EP4 signaling elicits immunosuppression by driving the mregDC-Treg axis in inflammatory tumor microenvironment. Cell Reports, 39,110914. doi: 10.1016/j.celrep.2022.110914
  5. SK2 channel modulation contributes to compartment-specific dendritic plasticity in cerebellar Purkinje cells. Ohtsuki G, Piochon C, Adelman JP, Hansel C. Neuron, Volume 75, Issue 1, 108-120; 12 Jul 2012, doi: 10.1016/j.neuron.2012.05.025


Professor and Chair: Hagiwara, Masatoshi
Professor: Narumiya, Shuh
Professor: Ohtsuki, Gen
Professor: Saotome, Chikako


  1. Home
  2. Research
  3. Research Fields